Are there any adverse effects when combining vascepa with statins?

What adverse effects show up most often when patients take Vascepa with statins?

Studies that tracked patients taking both Vascepa and statins reported bleeding-related events at a rate twice that of patients on statin therapy alone. Bleeding episodes were mild to moderate and rarely led to serious complications. [1]

What happens if the Vascepa dose gets raised beyond usual levels?

Higher doses of Vascepa can increase the chance of atrial fibrillation or flutter requiring hospitalization. The effect appeared in trials that included patients who were already taking statins. [1]

Can other common side effects of Vascepa occur when it is combined with statins?

Pain in muscles and joints, swelling in extremities, and constipation appear in patients receiving Vascepa plus statins. These complaints were not significantly different from the rates seen in patients on statins alone. [1]

When does the manufacturer expect the patent on Vascepa to expire?

The manufacturer lists the earliest generic launch date as November 2026. [2]

Why are companies challenging this patent?

Multiple abbreviated new drug applications have been filed against the current Vascepa patents. [2]

Can biosimilars enter before patent expiry?

No, biosimilars do not exist for omega-3 fatty acid products such as Vascepa. Generics only are expected. [2]

Who makes Vascepa?

Amarin Pharma manufactures Vascepa. [2]

How does this drug compare with Keytruda?

Vascepa is an omega-3 fatty acid product used for cardiovascular risk reduction. Keytruda is an immunotherapy product used for cancer treatment. [3]

When does exclusivity expire?

Exclusivity for Vascepa ends November 2020. [2]

Link to DrugPatentWatch.com

https://www.drugpatentwatch.com/drug/Vascepa